Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 10/20 | 0.75 |
| ▸ | JAK2 | O60674 | 5/20 | 0.64 |
| ▸ | JAK3 | P52333 | 4/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964729 | 0.86 | AXL (1.00) | AXLFGFR1 | |
| SCHEMBL21317668 | 0.85 | AXL (0.81) | AXLJAK2JAK3PTK2FGFR1 | |
| SCHEMBL12964797 | 0.84 | AXL (0.78) | AXLFGFR4FGFR1 | |
| SCHEMBL12964793 | 0.83 | AXL (0.74) | AXLJAK2JAK3ABL1KIT | |
| SCHEMBL25549942 | 0.81 | AXL (0.71) | AXLFGFR1ABL1KITBCR | |
| SCHEMBL12964796 | 0.81 | AXL (0.73) | AXLFGFR4 | |
| SCHEMBL25549973 | 0.80 | AXL (0.72) | AXLFGFR4FGFR1 | |
| SCHEMBL14536299 | 0.80 | AXL (0.65) | AXLJAK2JAK3PTK2FGFR1 | |
| SCHEMBL4561765 | 0.79 | CCNB2 (0.53) | AXLJAK2JAK3ABL1 | |
| SCHEMBL12813489 | 0.79 | AXL (0.77) | AXLJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO PHARMA ONCOLOGY, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10888562-B1 | — | — | 2021-01-12 | — | — | US | disclosed |
| EP-3628665-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | University of Utah Research Foundation (US) | 2020-04-01 | — | — | EP | disclosed |
| WO-2019195753-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | TOLERO PHARMACEUTICALS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2693881-B1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIV UTAH RES FOUND (US) | 2019-09-04 | — | — | EP | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901120-B2 | Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | SUMITOMO PHARMA ONCOLOGY, INC. | 2012-11-08 | — | — | US | disclosed |
| WO-2012135800-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283261-A1 | SUBSTITUTED N-PHENYLPYRIMIDIN-2-AMINE ANALOGS AS INHIBITORS OF THE AXL KINASE | AXL, TYRO3, MERTK | AXL 1/4885JAK2 97/4885JAK3 126/4885 |
| US-11013741-B1 | AXL kinase inhibitors and use of the same | AXL, FLT3, TEC | AXL 1/4885JAK2 74/4885JAK3 131/4885 |
| US-20210205304-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885JAK2 85/4885JAK3 150/4885 |
| US-20230165857-A1 | AXL KINASE INHIBITORS AND USE OF THE SAME | AXL, FLT3, TEC | AXL 1/4885JAK2 84/4885JAK3 160/4885 |
| US-10888562-B1 | — | TP53, TARBP2, FLT3 | AXL 927/4885JAK2 2109/4885JAK3 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.